1 day ago
EVENT
European Beer Pledge: fostering best practice in addressing alcohol misuse on Tuesday, 28 February 2012, European Parliament, Brussels.
The Beer Pledge is a voluntary initiative by Europe’s brewers to support EU member states in reducing alcohol related harm. The roundtable lunch on the launch of Europe’s brewers Beer Pledge initiative will focus on the following issues:
- improving consumer information and knowledge through a range of platforms including new technologies,
- ensuring responsible advertising,
- addressing alcohol misuse in line with the expectations of citizens and EU policymakers.
Registration and event website
Contact: Rachel Hewett
Tél: +32 2 741 8230
1 day ago
EVENT
A Roundtable Debate on breast cancer screening on Tuesday, 6 March 2012, European Parliament, Brussels.
‘An integrated approach to the early detection of breast cancer’ will bring together key stakeholders from the EU institutions, patient groups as well as the professional and scientific communities to raise awareness of the importance of early detection of breast cancer. It will identify obstacles to the uptake of screening across the EU, discuss best practice cases and introduce a new project as part of the EU Cancer Partnership (EPAAC) to tackle the issue.
The event will present a recent study by Siemens Healthcare on the attitudes of women towards breast cancer screening across several geographic regions.
Registration and event website
Contact: Rachel Hewett
tel: +32 2 741 8230
Email: rachel.hewett@dods.eu
EMA warnings for aliskiren-containing medicines
0European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines.
The European Medicines Agency finalised a review of aliskiren-containing medicines, recommending that these medicines should be contraindicated in patients with diabetes or moderate to severe renal impairment who take angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). In addition, the Agency recommended the inclusion of a warning that the combination of aliskiren and ACE inhibitor or ARB is not recommended in all other patients because adverse outcomes cannot be excluded. Doctors should stop prescribing aliskiren-containing medicines to patients with diabetes (type 1 or type 2) or with moderate to severe kidney impairment who are also taking an ACE inhibitor or ARB, and should consider alternative antihypertensive treatment as necessary.
For all other patients receiving aliskiren-containing medicines in combination with an ACE inhibitor or an ARB, the balance of benefits and risks of continuing treatment should be considered carefully. Patients should discuss their treatment with their doctor at their next scheduled (non-urgent) appointment. They should not stop any of their treatment before speaking to their doctor, because stopping anti-hypertensive medication without medical supervision can put them at risk. Patients in clinical trials with aliskiren should contact their study site for guidance on their medication.
For more information contact:
Fokion Sinis
Medical Information Sector
European Medicines Agency | 7 Westferry Circus | Canary Wharf | London E14 4HB | United Kingdom
Tel. +44 (0)20 7523 7432 | Fax +44 (0)20 7523 7129
fokion.sinis@ema.europa.eu | www.ema.europa.eu
20th International Conference on Health Promoting Hospitals
0Event
20th International Conference on Health Promoting Hospitals and Health Services (HPH) 11-13 April, 2012 Taipei, Taiwan
It will look back on what HPH originally set out to do, what the network has achieved so far, and what challenges and changes for the future lie ahead.
The Scientific Committee will highlight five major topics for the scientific program of the HPH conference 2012….more
EIWH’s New Website
0The European Institute of Women’s Health is redesigning and updating its website. Check out our new website.
International Childhood Cancer Day
05th February is International Childhood Cancer Day.
A European Parliament event to discuss how EU legislation has negatively affected the treatment received by children and adolescents has marked International Childhood Cancer. The meeting was hosted in association with the European Society for Paediatric Oncology (SIOPE) to raise awareness of the many hurdles faced by patients and those who care for them as a result of the EU Clinical Trials Directive (CTD).
The Directive (2001/20/EC) has been one of the most controversial pieces of European legislation related to health since its introduction in 2004; seen by many to be having a detrimental effect on academic-led clinical research in Europe. Member of the European Parliament Glenis Willmott, who hosted the event in Brussels, Belgium, stated: “EU countries are still using different standards for clinical trials, which means researchers have to apply multiple times for a clinical trial, with different applications.
This makes the whole process time-consuming, expensive, and sometimes futile. That’s why we want to make sure all EU countries are playing by the same rules. We need to do everything we can to encourage more research and more clinical trials, specifically designed for children and adolescents”.
SIOP EUROPE (the European Society for Paediatric Oncology)
Avenue E. Mounier 83, B-1200 Brussels, Belgium
tel: +32 2 775 02 01 fax: +32 2 775 02 00
www.siope.eu
Better Health for All – Promoting Gender Equity
018 October 2011 – A Roundtable of politicians, policy makers and a wide range of stakeholders with expertise in research, health policy and gender issues heard from the ENGENDER research team how to reduce inequalities in health by taking a more gender-sensitive approach to health policy, prevention, treatment and care.
Download the whole article as PDF here
Intelligent user interfaces workshop
0EVENT
Workshop – developing intelligent user interfaces for e-accessibility
14 February 2012 Lisbon, Portugal
The workshop will explore the applicability of different modalities of
interaction (speech, gesture, haptic interface etc.) and investigate
ways to develop intelligent adaptation systems that meet accessibility
criteria and can personalize interfaces according to the range of
abilities of the user.
A particular focus will be given on interoperability though the
adherence to standards for accessibility such as WAI-ARIA and ISO
standards.
Deadline for the submission of papers – 30th November 2011.
Guide project: http://www.guide-project.eu/
Augmented Human International Conference
0EVENT
Call for papers for Augmented Human International Conference (AH 2012)
8 March 2012 – 9 March 2012 Megeve, France
The third Augmented Human (AH) International Conference focuses on
scientific contributions towards augmenting humans capabilities through
technology for increased well-being and enjoyable human experience. The
papers and contributions from the art researchers and practitioners are
especially welcomed. Paper submission deadline – 13/01/2012.
eHealth at the EC: http://ec.europa.eu/ehealth
Commission requests Estonia and Slovakia to comply with public sector information rules
0EU Commission has requested Estonia and Slovakia to bring their laws in
line with EU rules on re-use of public sector information (PSI). These
countries are not guaranteeing fair conditions for re-use of public
sector information, in breach of the EU’s PSI Directive.
Estonia and Slovakia have failed to correctly implement most provisions of the
Directive, including prohibiting discriminatory or monopolistic
practices by public bodies.